DUBLIN, Ireland and TREVOSE, Pa., May 25, 2017 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that management will present at the Jefferies 2017 Global Healthcare Conference, taking place June 6-9 at the Grand Hyatt in New York City.
Matthew Pauls, president and chief executive officer of Strongbridge Biopharma, will provide a corporate overview on Friday, June 9 at 10:30 a.m. ET. The presentation will be webcast live and archived on the “Events & Presentations” page in the Investor section of the Company’s website at www.strongbridgebio.com.
About Strongbridge Biopharma
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's first commercial product is KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis. KEVEYIS has orphan drug exclusivity status in the U.S. through August 7, 2022. In addition to establishing this neuromuscular disease franchise, the Company has a clinical-stage pipeline of therapies for rare endocrine diseases. Strongbridge's lead compounds include RECORLEV™ (levoketoconazole), a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome, and veldoreotide, a next-generation somatostatin analog being investigated for the treatment of acromegaly, with potential additional applications in Cushing's syndrome and neuroendocrine tumors. Both RECORLEV and veldoreotide have received orphan designation from the U.S. Food and Drug Administration and the European Medicines Agency. For more information, visit www.strongbridgebio.com.